Source: Annual Congress 2009 - Treatment of airways disease
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Slepchenko, A. Sidorov, Y. Mostovoy (Vinnitsa, Ukraine). Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP). Eur Respir J 2009; 34: Suppl. 53, 2075

Member's Comments

No comment yet.

Related content which might interest you: Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Atypical agents of community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 485s Year: 2003 Biomarkers and severity in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Biomarkers in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Legionella pneumonia in patients hospitalized with community-acquired pneumonia (CAP) in Norway Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Epidemiology of community-acquired pneumonia (CAP) Source: International Congress 2015 – Russia Day: Community-acquired pneumonia (CAP) in adults Year: 2015 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Etiology of community-acquired pneumonia (CAP) in young hospital patients Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002 Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006 Applicability of Fine criteria in patients hospitalized for community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 67s Year: 2005 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Comparison of costs of community-acquired pneumonia (CAP) treatment at patients with and without bronchial obstruction Source: Annual Congress 2011 - COPD management Year: 2011 Discharge delay in patients with community-acquired pneumonia (CAP) treated with a pneumonia critical pathway Source: Eur Respir J 2002; 20: Suppl. 38, 560s Year: 2002 Outpatient treatment of community-acquired pneumonia in the elderly Source: Eur Respir J 2002; 20: Suppl. 38, 355s Year: 2002 Optimizing treatment for community-acquired pneumonia in Denmark (The optiCAP study) Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Mixed community-acquired pneumonia in hospitalised patients Source: Eur Respir J 2006; 27: 795-800 Year: 2006